Dose modification of lumacaftor/ivacaftor and the immediate effects on lung function in cystic fibrosis patients with advanced lung disease and 12-month outcomes in this cohort: IPD2.08

Natalia Popowicz, J. Wood, S. Vekaria, A. Tai, S. Morey, S. Mulrennan

Research output: Contribution to conferencePosterpeer-review

Original languageEnglish
PagesS55-S56
DOIs
Publication statusPublished - Jun 2018
Event41st European Cystic Fibrosis Conference 2018 - Belgrade, Serbia
Duration: 6 Jun 20189 Jun 2018

Conference

Conference41st European Cystic Fibrosis Conference 2018
Country/TerritorySerbia
CityBelgrade
Period6/06/189/06/18

Cite this